Shares in BioLogics, which had risen 7.1% a day earlier after local media reports about a potential spin-off, rose as much as 8.2% on Thursday before paring gains.

Samsung Biologics, the biopharmaceutical arm of Samsung Group, said on May 26 it had secured two contract manufacturing deals worth a combined 4.4 trillion won ($320 million) with European and ...

Samsung Biologics operates with manageable financial health in our view. Its debt/EBITDA ratios were 1.5, 1.0, and 0.70 times for 2022, 2023, and 2024, respectively.

INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung ...

Samsung Biologics plans to spin off its biosimilars business. And more. 1. Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck ...

Samsung Biologics, one of the world's largest contract development and manufacturing organizations, or CDMOs, announced Wednesday that it posted record-high $1.88 billion in sales during the first ...

SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025.

Samsung Bio’s strong quarter is nothing new for the company, which reported full-year 2024 sales growth of 23% to 4.55 trillion won ($3.3 billion) back in January.